Key Points
Key Points
- Shares rose 14.21% to $225 on October 9, highest since 2022
- NIH plans December launch of cancer vaccine partnership
- Phase 3 trial showed 49% lower recurrence risk in melanoma
On This Page
Moderna’s stock exploded higher on October 9, 2026, closing up 14.21 percent at 225 dollars, its highest level since January 2022. The trigger was a New York Times report that the National Institutes of Health is planning a public-private partnership to speed up cancer vaccine development, with a launch expected in December.
The initiative will focus on pancreatic, liver and colorectal cancers, along with certain childhood tumours. It is modelled on the collaboration that produced COVID-19 vaccines.
A remarkable year
The rally extends an August surge driven by landmark Phase 3 results for Moderna and Merck’s personalised mRNA cancer vaccine, intismeran autogene. The trial met its primary endpoint with a 49 percent reduction in the risk of recurrence or death in patients with completely resected stage IIB to IV melanoma.
Moderna shares are up 663 percent in 2026, making it the best-performing stock in the S&P 500 this year. Its market value now stands near 90 billion dollars.
Why Moderna leads
Analysts view Moderna as the clear leader in mRNA cancer treatments, with the only positive Phase 3 readout for an mRNA cancer therapy. The company has a purpose-built factory in Marlborough, Massachusetts, for making individualised neoantigen therapies, plus an established partnership with Merck.
Reasons for caution
Not everyone is convinced. The average analyst price target sits far below the current share price, and short sellers have lost about 4.8 billion dollars betting against the stock this year. Projected 2026 free cash flow remains negative.
Experts say cancer vaccines remain experimental, and investors should weigh the science alongside the hype.
How the vaccine works
Moderna’s personalised vaccine is built around neoantigens, unique protein fragments found on a patient’s own tumour. Scientists sequence the tumour, identify its mutations and design an mRNA vaccine that teaches the immune system to attack those specific targets.
Combined with Merck’s Keytruda, which removes the brakes from immune cells, the vaccine helps the body hunt down remaining cancer cells after surgery. Each dose is custom-made for one patient.
The road ahead
The NIH partnership aims to replicate the COVID-19 playbook for cancer. Government scientists, academic centres and companies would share data and resources to speed up trials. Pancreatic cancer, one of the deadliest tumours, is a top priority.
Challenges remain. Personalised vaccines are expensive and complex to manufacture. Proving they work in tougher cancers will take years of further trials.
Merck and Moderna expect to file for regulatory approval of their melanoma vaccine in the coming years. Trials in lung cancer and other tumours are already under way. If the approach succeeds more broadly, personalised cancer vaccines could become a new pillar of oncology alongside surgery, radiation and chemotherapy.
React to this story
